Journal Mobile Options
Table of Contents
Vol. 21, Suppl. 2, 2006
Issue release date: May 2006

The Ischemic Penumbra: A New Opportunity for Neuroprotection

Fisher M.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


The development of acute stroke therapies has yielded only limited success and many failures in multiple clinical trials. The target of acute stroke therapy is that portion of the ischemic region that is still potentially salvageable, i.e. the ischemic penumbra. Neuroprotective drugs have the potential to prevent a portion of the ischemic penumbra from evolving into infracted tissue and designing trials that target neuroprotective drugs at patients with persistent penumbra should enhance the likelihood of a positive outcome. Currently, diffusion and perfusion MRI has the potential to approximate the location and persistence of the ischemic penumbra and can be used in clinical trials to select appropriate patients for inclusion and to evaluate a meaningful treatment effect. Perfusion CT may also have similar capabilities. Use of these imaging modalities in clinical trials and ultimately in clinical practice will likely help in the development and utilization of novel neuroprotective drugs.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Kidwell CS, Liebeskind DS, Starkman S, Saver JL: Trends in acute ischemic stroke trials through the 20th century. Stroke 2001;32:1349–1359.
  2. The ATLANTIS, ECASS and NINDS rt-PA Study Group Investigators: Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS and NINDS rt-PA stroke trials. Lancet 2004;363:768–774.
  3. Fisher M: Characterizing the target of acute stroke treatment. Stroke 1997;28:866–872.
  4. Lees KR, Zivin JA, Ashwood T, Davalos A, Davis SM, Diener HC, Grotta J, Lyden P, Shuaib A, Hardemark HG, Wasiewski WW, Stroke-Acute Ischemic NXY Treatment (SAINT I) Trial Investigators: NXY-059 for acute ischemic stroke. N Engl J Med 2006;354:588–600.
  5. Fisher M: The ischemic penumbra: identification, evolution and treatment concepts. Cerebrovasc Dis 2004;17(suppl 1):1–6.
  6. Astrup J, Siesjo BK, Symon L: Thresholds in cerebral ischemia: the ischemic penumbra. Stroke 1981;12:723–725.
  7. Hakim AM: The cerebral ischemic penumbra. Can J Neurol Sci 1987;14:557–559.
  8. Fisher M, Ratan R: New perspectives on developing acute stroke therapy. Ann Neurol 2003;53:10–20.
  9. Cheng YD, Al-Khoury L, Zivin JA: Neuroprotection for ischemic stroke: two decades of success and failure. NeuroRx 2000;1:36–45.

    External Resources

  10. Schlaug G, Benfield A, Baird AE, et al: The ischemic penumbra: operationally defined by diffusion perfusion MRI. Neurology 1999;53:1528–1537.
  11. Parsons MW, Barber A, Chalk J, et al: Diffusion and perfusion-weighted MRI response to thrombolysis in stroke. Ann Neurol 2002;51:28–37.
  12. Van der Toorn A, Sykova E, Dijkhuizen RM, et al: Dynamic changes in water ADC, energy metabolism, extracellular space volume and tortuosity in neonatal rat brain during global ischemia. Magn Res Med 1996;36:52–60.
  13. Li F, Liu KF, Silva, et al: Secondary decline in apparent diffusion coefficient and neurological outcome after a short period of focal brain ischemia in rats. Ann Neurol 2000;48:236–244.
  14. Kidwell CS, Saver JL, Mattiello J, et al: Thrombolytic reversal of acute human cerebral ischemic injury shown by diffusion/perfusion magnetic resonance imaging. Ann Neurol 2000;47:462–469.
  15. Calamante F, Thomas DL, Pell GS, Wiersma J, Turner R: Measuring cerebral blood flow using magnetic resonance imaging techniques. J Cereb Blood Flow Metab 1999;19:701–735.
  16. Butcher KS, Parsons M, MacGregor L, et al: Refining the perfusion-diffusion mismatch hypothesis. Stroke 2005;36:1153–1159.
  17. Kidwell CS, Alger JR, Saver JL: Beyond mismatch: evolving paradigms in imaging the ischemic penumbra with multimodal magnetic resonance imaging. Stroke 2003;34:2729–2735.
  18. Shen Q, Fisher M, Sotak CH, Duong TQ: Effect of reperfusion on ADC and CBF pixel-by-pixel dynamics in stroke: characterizing tissue fates using quantitative diffusion and perfusion imaging. J Cereb Blood Flow Metab 2004:24:280–290.
  19. Wintermark M, Bogousslavsky J, Thiren JP, et al: Prognostic accuracy of admission cerebral blood flow measurements by perfusion CT in acute stroke patients. Ann Neurol 2002;51:417–432.
  20. Schramm P, Schellinger PD, Klotz E, et al: Comparison of perfusion computed tomography angiography source images with perfusion-weighted imaging and diffusion-weighted imaging in patients with acute stroke less than 6 hours’ duration. Stroke 2004;35:1652–1658.
  21. Warach S, Pettigrew LC, Dashe JF, Pullicino P, Lefkowitz DM, Sabounjian L: Effects of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Citicoline 010 Investigators. Ann Neurol 2000;48:713–722.
  22. Neumann-Haeflin T, de Rochemont M, Fiebach JB, et al: Effect of incomplete (spontaneous and postthrombolytic) recanalization after middle artery occlusion. Stroke 2004;35:109–115.
  23. Ribo M, Molina CA, Rovira A, et al: Safety and efficacy of intravenous tissue plasminogen activator in the 3- to 6-hour window using multimodal transcranial Doppler/MRI selection protocol. Stroke 2005;36:602–606.
  24. Lev MH, Segal AZ, Farkas J, et al: Utility of perfusion-weighted CT imaging in acute middle cerebral artery stroke treated with intra-arterial thrombolysis: prediction of final infarct volume and clinical outcome. Stroke 2002;33:2426–2432.
  25. Warach S: Use of diffusion and perfusion magnetic resonance imaging as a tool in acute stroke clinical trials. Curr Control Trials Cardiovasc Med 2001;2:38–44.
  26. Warach S: Sabounjian LA: ECCO 2000 study of citicoline for treatment of acute ischemic stroke: effects on infarct volume measured by MRI (abstract). Stroke 2000;31:42.
  27. Hacke W, Albers G, Al-Rawi Y, et al: The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005;36:66–73.
  28. Hacke W for the DIAS and DEDAS Steering Committees and Investigators: The results of the joint analysis of two phase II trials of desmoteplase in acute ischemic stroke with treatment 3–9 hours after stroke onset. 15th European Stroke Conference, Bologna, May 2005.
  29. Katz R: Biomarkers and surrogate endpoints: an FDA perspective. NeuroRx 2004;1:189–195

    External Resources

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50